• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

克唑替尼与奥希替尼联合治疗T790M+表皮生长因子受体（EGFR）突变型非小细胞肺癌：一名10年生存者在奥希替尼进展后出现MET扩增的病例报告

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.

作者信息

Blasi Miriam, Kazdal Daniel, Thomas Michael, Christopoulos Petros, Kriegsmann Mark, Brandt Regine, Volckmar Anna-Lena, Kirchner Martina, Heußel Claus Peter, Stenzinger Albrecht, Kuon Jonas

机构信息

Department of Thoracic Oncology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

出版信息

Case Rep Oncol. 2021 Mar 18;14(1):477-482. doi: 10.1159/000513904. eCollection 2021 Jan-Apr.

DOI:10.1159/000513904
PMID:33976623
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8077408/
Abstract

Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both first- and second-generation agents such as oncogene amplification. This report describes the successful results obtained with the combination of the third-generation TKI osimertinib with the multitargeted TKI and MET inhibitor crizotinib in a patient with EGFR-mutant NSCLC with emerging MET amplification with a tolerable toxicity profile.

摘要

酪氨酸激酶抑制剂（TKIs）是表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者的标准治疗方法。然而，由于对第一代和第二代药物（如癌基因扩增）产生耐药机制，反应持续时间在时间上是有限的。本报告描述了第三代TKI奥希替尼与多靶点TKI和MET抑制剂克唑替尼联合应用于一名出现MET扩增且毒性可耐受的EGFR突变NSCLC患者所取得的成功结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b10/8077408/5dba3d3f4134/cro-0014-0477-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b10/8077408/d583aafc8194/cro-0014-0477-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b10/8077408/5dba3d3f4134/cro-0014-0477-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b10/8077408/d583aafc8194/cro-0014-0477-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b10/8077408/5dba3d3f4134/cro-0014-0477-g02.jpg

相似文献

1
Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.克唑替尼与奥希替尼联合治疗T790M+表皮生长因子受体（EGFR）突变型非小细胞肺癌：一名10年生存者在奥希替尼进展后出现MET扩增的病例报告
Case Rep Oncol. 2021 Mar 18;14(1):477-482. doi: 10.1159/000513904. eCollection 2021 Jan-Apr.
2
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.克唑替尼联合或不联合 EGFR-TKI 治疗 EGFR 突变型 NSCLC 患者 EGFR-TKI 治疗失败后获得性 MET 扩增：一项多中心回顾性研究。
J Transl Med. 2019 Feb 21;17(1):52. doi: 10.1186/s12967-019-1803-9.
3
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with -mutant non-small cell lung cancer and emergent amplification.一名携带 - 突变的非小细胞肺癌且出现 扩增的患者对全剂量奥希替尼和克唑替尼联合用药的差异反应
Lung Cancer (Auckl). 2019 Mar 12;10:21-26. doi: 10.2147/LCTT.S190403. eCollection 2019.
4
Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?我们能否确定表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变的非小细胞肺癌的最佳用药顺序？
Curr Opin Oncol. 2017 Mar;29(2):89-96. doi: 10.1097/CCO.0000000000000350.
5
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.表皮生长因子受体（EGFR）突变的非小细胞肺癌在一线酪氨酸激酶抑制剂治疗中出现疾病进展时的优化管理。
Lung Cancer. 2017 Aug;110:7-13. doi: 10.1016/j.lungcan.2017.05.009. Epub 2017 May 11.
6
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.表皮生长因子受体酪氨酸激酶抑制剂的发展以及应对第三代表皮生长因子受体酪氨酸激酶抑制剂奥希替尼耐药的策略：传统方法与免疫检查点抑制剂
Front Oncol. 2020 Dec 18;10:602762. doi: 10.3389/fonc.2020.602762. eCollection 2020.
7
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.表皮生长因子受体突变的非小细胞肺癌中的下一代表皮生长因子受体酪氨酸激酶抑制剂
Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8.
8
Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.表皮生长因子受体（EGFR）突变阳性非小细胞肺癌患者一线 EGFR 酪氨酸激酶抑制剂治疗后治疗模式的观察性研究。
Adv Ther. 2020 Feb;37(2):946-954. doi: 10.1007/s12325-020-01221-4. Epub 2020 Jan 18.
9
Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.奥希替尼治疗肺鳞状细胞癌对第一代EGFR-TKI获得性耐药的显著疗效：一例报告
World J Clin Cases. 2019 May 26;7(10):1221-1229. doi: 10.12998/wjcc.v7.i10.1221.
10
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.克唑替尼治疗 EGFR TKI 治疗后出现 cMET 扩增的 EGFR 突变阳性 NSCLC 患者，导致短暂和异质性反应。
Lung Cancer. 2018 Oct;124:130-134. doi: 10.1016/j.lungcan.2018.07.030. Epub 2018 Jul 30.

引用本文的文献

1
Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo Amplification in Patients with Metastatic -Mutated NSCLC.针对转移性 - 突变型 NSCLC 患者获得性和从头扩增的 EGFR-TKI 和克唑替尼联合治疗的真实世界数据。
Int J Mol Sci. 2023 Aug 23;24(17):13077. doi: 10.3390/ijms241713077.
2
Next-generation sequencing-based detection in a breast MMPMN patient with EGFR T790M mutation: a rare case report and literature review.基于下一代测序的表皮生长因子受体T790M突变乳腺黏液性微乳头状癌患者检测：一例罕见病例报告及文献综述
Front Oncol. 2023 Jul 24;13:1204041. doi: 10.3389/fonc.2023.1204041. eCollection 2023.
3

本文引用的文献

1
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.MET 抑制剂在 EGFR TKI 耐药肺癌的靶向治疗中的应用。
J Hematol Oncol. 2019 Jun 21;12(1):63. doi: 10.1186/s13045-019-0759-9.
2
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with -mutant non-small cell lung cancer and emergent amplification.一名携带 - 突变的非小细胞肺癌且出现 扩增的患者对全剂量奥希替尼和克唑替尼联合用药的差异反应
Lung Cancer (Auckl). 2019 Mar 12;10:21-26. doi: 10.2147/LCTT.S190403. eCollection 2019.
3
Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.
Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
在接受挽救性治疗的有 BM/LM 的晚期 NSCLC 患者中，富马酸福莫替尼 160mg 联合或不联合抗血管生成药物的颅内疗效和安全性。
BMC Cancer. 2023 Mar 4;23(1):206. doi: 10.1186/s12885-023-10676-x.
4
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.在高度异质肿瘤模型中评估 EGFR 酪氨酸激酶抑制剂联合治疗的临床前评估。
Oncogene. 2022 Apr;41(17):2470-2479. doi: 10.1038/s41388-022-02263-4. Epub 2022 Mar 19.
携带 MET 扩增的 EGFR 突变型肺癌患者的突变监测：吉非替尼和克唑替尼治疗有效。
Lung Cancer. 2019 Mar;129:72-74. doi: 10.1016/j.lungcan.2019.01.009. Epub 2019 Jan 23.
4
Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review.吉非替尼耐药后，克唑替尼与吉非替尼联合用于伴有软脑膜转移且MET扩增的晚期肺腺癌：一例报告及文献综述
Clin Lung Cancer. 2019 May;20(3):e251-e255. doi: 10.1016/j.cllc.2018.12.004. Epub 2018 Dec 19.
5
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.在EGFR突变的非小细胞肺癌中，T790M阳性后相继出现MET扩增时，全剂量克唑替尼与奥希替尼联合使用的耐受性及有效性
J Thorac Oncol. 2017 Jul;12(7):e85-e88. doi: 10.1016/j.jtho.2017.02.020. Epub 2017 Mar 6.
6
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.T790M 阳性非小细胞肺癌中的第三代表皮生长因子受体-酪氨酸激酶抑制剂：耐药新机制综述
Transl Lung Cancer Res. 2016 Dec;5(6):695-708. doi: 10.21037/tlcr.2016.12.02.
7
Mechanisms of resistance to EGFR-targeted drugs: lung cancer.表皮生长因子受体（EGFR）靶向药物的耐药机制：肺癌
ESMO Open. 2016 May 11;1(3):e000060. doi: 10.1136/esmoopen-2016-000060. eCollection 2016.
8
High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.在一名奥希替尼进展后对克唑替尼治疗有症状反应的患者中，高MET扩增水平作为对奥希替尼（AZD9291）的耐药机制。
Lung Cancer. 2016 Aug;98:59-61. doi: 10.1016/j.lungcan.2016.05.015. Epub 2016 May 25.
9
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.癌基因互换作为肺癌中获得性表皮生长因子受体-酪氨酸激酶抑制剂耐药的一种新机制。
Cancer Sci. 2016 Apr;107(4):461-8. doi: 10.1111/cas.12905. Epub 2016 Mar 28.
10
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.阿法替尼治疗表皮生长因子受体抑制剂耐药的非小细胞肺癌
N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.